vs
BED BATH & BEYOND, INC.（BBBY）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
BED BATH & BEYOND, INC.的季度营收约是Ultragenyx Pharmaceutical Inc.的1.2倍（$247.8M vs $207.3M），BED BATH & BEYOND, INC.净利率更高（-6.6% vs -62.0%，领先55.4%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 6.9%），BED BATH & BEYOND, INC.自由现金流更多（$-12.8M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -21.1%）
Bed Bath & Beyond曾是美国大型零售连锁企业，主营家居用品、家具及特色家居商品，总部位于新泽西州尤宁郡，业务覆盖美国与加拿大，曾经一度跻身财富世界500强与福布斯全球2000强榜单。该企业于2023年4月申请破产清算，关闭所有剩余门店，现已转型为线上零售品牌。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
BBBY vs RARE — 直观对比
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.8M | $207.3M |
| 净利润 | $-16.4M | $-128.6M |
| 毛利率 | 23.9% | — |
| 营业利润率 | 68.8% | -54.7% |
| 净利率 | -6.6% | -62.0% |
| 营收同比 | 6.9% | 25.9% |
| 净利润同比 | 58.9% | 3.5% |
| 每股收益（稀释后） | $-0.24 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | $247.8M | — | ||
| Q4 25 | $273.4M | $207.3M | ||
| Q3 25 | $257.2M | $159.9M | ||
| Q2 25 | $282.3M | $166.5M | ||
| Q1 25 | $231.7M | $139.3M | ||
| Q4 24 | $303.2M | $164.6M | ||
| Q3 24 | $311.4M | $139.5M | ||
| Q2 24 | $398.1M | $147.0M |
| Q1 26 | $-16.4M | — | ||
| Q4 25 | $-20.9M | $-128.6M | ||
| Q3 25 | $-4.5M | $-180.4M | ||
| Q2 25 | $-19.3M | $-115.0M | ||
| Q1 25 | $-39.9M | $-151.1M | ||
| Q4 24 | $-81.3M | $-133.2M | ||
| Q3 24 | $-61.0M | $-133.5M | ||
| Q2 24 | $-42.6M | $-131.6M |
| Q1 26 | 23.9% | — | ||
| Q4 25 | 24.6% | — | ||
| Q3 25 | 25.3% | — | ||
| Q2 25 | 23.7% | — | ||
| Q1 25 | 25.1% | — | ||
| Q4 24 | 23.0% | — | ||
| Q3 24 | 21.2% | — | ||
| Q2 24 | 20.1% | — |
| Q1 26 | 68.8% | — | ||
| Q4 25 | -4.8% | -54.7% | ||
| Q3 25 | -4.8% | -106.9% | ||
| Q2 25 | -4.4% | -64.8% | ||
| Q1 25 | -10.0% | -102.6% | ||
| Q4 24 | -11.3% | -74.3% | ||
| Q3 24 | -14.5% | -94.6% | ||
| Q2 24 | -11.8% | -79.1% |
| Q1 26 | -6.6% | — | ||
| Q4 25 | -7.6% | -62.0% | ||
| Q3 25 | -1.8% | -112.8% | ||
| Q2 25 | -6.8% | -69.0% | ||
| Q1 25 | -17.2% | -108.5% | ||
| Q4 24 | -26.8% | -80.9% | ||
| Q3 24 | -19.6% | -95.7% | ||
| Q2 24 | -10.7% | -89.5% |
| Q1 26 | $-0.24 | — | ||
| Q4 25 | $-0.26 | $-1.28 | ||
| Q3 25 | $-0.07 | $-1.81 | ||
| Q2 25 | $-0.34 | $-1.17 | ||
| Q1 25 | $-0.74 | $-1.57 | ||
| Q4 24 | $-1.68 | $-1.34 | ||
| Q3 24 | $-1.33 | $-1.40 | ||
| Q2 24 | $-0.93 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $135.8M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $202.5M | $-80.0M |
| 总资产 | $404.5M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | $135.8M | — | ||
| Q4 25 | $175.3M | $421.0M | ||
| Q3 25 | $167.4M | $202.5M | ||
| Q2 25 | $120.6M | $176.3M | ||
| Q1 25 | $114.6M | $127.1M | ||
| Q4 24 | $159.2M | $174.0M | ||
| Q3 24 | $140.4M | $150.6M | ||
| Q2 24 | $186.2M | $480.7M |
| Q1 26 | $202.5M | — | ||
| Q4 25 | $217.6M | $-80.0M | ||
| Q3 25 | $202.6M | $9.2M | ||
| Q2 25 | $130.9M | $151.3M | ||
| Q1 25 | $143.4M | $144.2M | ||
| Q4 24 | $162.7M | $255.0M | ||
| Q3 24 | $196.2M | $346.8M | ||
| Q2 24 | $250.4M | $432.4M |
| Q1 26 | $404.5M | — | ||
| Q4 25 | $425.5M | $1.5B | ||
| Q3 25 | $414.4M | $1.2B | ||
| Q2 25 | $358.1M | $1.3B | ||
| Q1 25 | $363.7M | $1.3B | ||
| Q4 24 | $402.0M | $1.5B | ||
| Q3 24 | $428.3M | $1.5B | ||
| Q2 24 | $496.8M | $1.6B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-11.8M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-12.8M | $-100.8M |
| 自由现金流率自由现金流/营收 | -5.2% | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-24.8M | $-472.0M |
8季度趋势，按日历期对齐
| Q1 26 | $-11.8M | — | ||
| Q4 25 | $-6.5M | $-99.8M | ||
| Q3 25 | $-15.1M | $-91.4M | ||
| Q2 25 | $15.8M | $-108.3M | ||
| Q1 25 | $-50.9M | $-166.5M | ||
| Q4 24 | $-21.7M | $-79.3M | ||
| Q3 24 | $-42.1M | $-67.0M | ||
| Q2 24 | $-75.9M | $-77.0M |
| Q1 26 | $-12.8M | — | ||
| Q4 25 | $-8.6M | $-100.8M | ||
| Q3 25 | $-17.4M | $-92.7M | ||
| Q2 25 | $14.0M | $-110.7M | ||
| Q1 25 | $-52.1M | $-167.8M | ||
| Q4 24 | $-24.7M | $-79.5M | ||
| Q3 24 | $-45.5M | $-68.6M | ||
| Q2 24 | $-80.4M | $-79.0M |
| Q1 26 | -5.2% | — | ||
| Q4 25 | -3.2% | -48.6% | ||
| Q3 25 | -6.8% | -58.0% | ||
| Q2 25 | 5.0% | -66.5% | ||
| Q1 25 | -22.5% | -120.5% | ||
| Q4 24 | -8.1% | -48.3% | ||
| Q3 24 | -14.6% | -49.2% | ||
| Q2 24 | -20.2% | -53.7% |
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | 0.5% | ||
| Q3 25 | 0.9% | 0.8% | ||
| Q2 25 | 0.6% | 1.5% | ||
| Q1 25 | 0.5% | 1.0% | ||
| Q4 24 | 1.0% | 0.1% | ||
| Q3 24 | 1.1% | 1.2% | ||
| Q2 24 | 1.1% | 1.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BBBY
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
